Momenta Pharmaceuticals to Host R&D Day on October 11, 2018
Momenta’s leadership team plans to highlight the clinical development strategy for its pipeline of novel drug candidates for immune-mediated disorders. Presentations will include:
- Data from the Phase 1 study in healthy volunteers for M281, a potentially best-in-class anti-FcRn antibody engineered to reduce circulating pathogenic IgG antibodies by blocking endogenous IgG recycling via FcRn, and the indications for the planned Phase 2 proof of concept studies. Momenta will be joined by a key opinion leader to discuss one of the indications;
- Overview of the Phase 1/2 proof of concept study in idiopathic thrombocytopenic purpura (ITP) for M254, a hyper-sialylated immunoglobulin (hsIgG) designed as a high potency alternative to intravenous immunoglobulin (IVIg) to remediate limitations of that therapeutic approach; and
- Overview of Momenta’s research platform and additional pipeline expansion opportunities.
The live webcast of this event will be accessible through the "Investors" section of the company's website located at www.momentapharma.com. A webcast replay of the presentation will be posted on the Momenta website approximately two hours after the event.
Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta’s lead product candidate, M281, is a potentially best-in-class anti-FcRn antibody; M254, is a hyper-sialylated human immunoglobulin (hsIgG) designed as a high potency alternative to intravenous immunoglobulin (IVIg); and M230 (CSL730), is a potential first-in-class novel recombinant Fc multimer being developed in collaboration with CSL. Momenta also has a focused pipeline of two biosimilar candidates: M710, a proposed biosimilar to EYLEA® being developed in collaboration with Mylan, and M923, Momenta’s wholly-owned proposed biosimilar to HUMIRA®. Momenta’s two
To learn more about Momenta, please visit www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the timing and content of our proposed presentations regarding Phase 1 data and indications for Phase 2 studies for M28, plans regarding timing of studies for M254, and potential research and pipeline expansions. Forward-looking statements may be identified by words such as "believe," "continue," “plan to”, "potential," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including the risk that we are unable to make such presentations or that the content of such presentations will change; and those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended
|INVESTOR CONTACT:||MEDIA CONTACT:|
|Sarah Carmody||Karen Sharma|
|Momenta Pharmaceuticals||MacDougall Biomedical Communications|
Source: Momenta Pharmaceuticals, Inc.